Status:
COMPLETED
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Lead Sponsor:
Children's Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Childhood Acute Erythroleukemia (M6)
Childhood Acute Megakaryocytic Leukemia (M7)
Eligibility:
All Genders
Up to 21 years
Brief Summary
This research study is studying identification of de novo Fanconi anemia in younger patients with newly diagnosed acute myeloid leukemia. Studying samples of tissue from patients with cancer in the la...
Detailed Description
PRIMARY OBJECTIVES: I. Identify children with newly diagnosed acute myeloid leukemia (AML) treated on COG-2961 and COG-AAML03P1 who are at high risk of having de novo Fanconi anemia. II. Procure dia...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Treated on COG-2961 or COG-AAML03P1
- At high risk of having Fanconi anemia, defined as meeting one the following groups of clinical criteria:
- Group 1: Prolonged neutropenia after induction, severe regimen-related toxicity (mucositis, veno-occlusive disease, end-organ damage)
- Group 2: Early non-relapse death (induction, consolidation)
- Group 3: Small-for-weight, secondary malignancies
Exclusion
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01146210
Start Date
May 1 2009
End Date
May 1 2016
Last Update
May 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Oncology Group
Monrovia, California, United States, 91006-3776